Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE6D | O43924 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | MGLL | Q99685 | 2/20 | 0.40 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.33 |
| ▸ | CDC25A | P30304 | 1/20 | 0.32 |
| ▸ | CDC25B | P30305 | 1/20 | 0.32 |
| ▸ | CDC25C | P30307 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19938532 | 0.97 | PDE6D (0.40) | PDE6DFAAHMGLLP2RX4CDC25A | |
| SCHEMBL19938610 | 0.91 | P2RX4 (0.37) | MGLLP2RX4ALDH1A1 | |
| SCHEMBL19938598 | 0.89 | MGLL (0.48) | PDE6DFAAHMGLLCDC25ACDC25B | |
| SCHEMBL19938523 | 0.88 | P2RX4 (0.37) | MGLLP2RX4ALDH1A1 | |
| SCHEMBL19938563 | 0.82 | PDE6D (0.38) | PDE6DFAAHMGLLP2RX4PTPN1 | |
| SCHEMBL19938490 | 0.82 | PDE6D (0.38) | PDE6DFAAHMGLLP2RX4PTPN1 | |
| SCHEMBL19939076 | 0.82 | GAA (0.37) | MGLLP2RX4ALDH1A1 | |
| SCHEMBL19939086 | 0.82 | GAA (0.33) | MGLLP2RX4ALDH1A1 | |
| SCHEMBL19939110 | 0.82 | — | — | |
| SCHEMBL19938536 | 0.81 | P2RX4 (0.40) | MGLLP2RX4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11653565-B2 | Polycyclic aromatic compound | KWANSEI GAKUIN EDUCATIONAL FOUNDATION (JP) | 2023-05-16 | — | — | US | disclosed |
| US-11653565-B2 | Polycyclic aromatic compound | KWANSEI GAKUIN EDUCATIONAL FOUNDATION (JP) | 2023-05-16 | — | — | US | disclosed |
| US-20200220083-A1 | POLYCYCLIC AROMATIC COMPOUND | KWANSEI GAKUIN EDUCATIONAL FOUNDATION (JP) | 2020-07-09 | — | — | US | disclosed |
| US-10686141-B2 | Polycyclic aromatic compound | KWANSEI GAKUIN EDUCATIONAL FOUNDATION (JP) | 2020-06-16 | — | — | US | disclosed |
| US-20180069182-A1 | POLYCYCLIC AROMATIC COMPOUND | KWANSEI GAKUIN EDUCATIONAL FOUNDATION (JP) | 2018-03-08 | — | — | US | disclosed |
| US-20180069182-A1 | POLYCYCLIC AROMATIC COMPOUND | KWANSEI GAKUIN EDUCATIONAL FOUNDATION (JP) | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11653565-B2 | Polycyclic aromatic compound | ETV6, EBPL, EML4 | PDE6D 4796/4885FAAH 3478/4885MGLL 3731/4885 |
| US-10686141-B2 | Polycyclic aromatic compound | ETV6, EBPL, EML4 | PDE6D 4796/4885FAAH 3478/4885MGLL 3731/4885 |
| US-20180069182-A1 | POLYCYCLIC AROMATIC COMPOUND | ETV6, EBPL, EML4 | PDE6D 4796/4885FAAH 3478/4885MGLL 3731/4885 |
| US-20200220083-A1 | POLYCYCLIC AROMATIC COMPOUND | ETV6, EBPL, EML4 | PDE6D 4796/4885FAAH 3478/4885MGLL 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.